Credit: Shutterstock photoASLAN Pharmaceuticals, a Singapore biotech developing cancer therapies using the HER pathway, raised $42 million in its US initial public offering. Listed on the Taiwan Stock Exchange, ASLAN offered a downsized 6.0 million ADSs at $7.03. The company had initially filed to sell 7.5 million ADSs. At pricing, the company commands a market value of $235 million.
ASLAN Pharmaceuticals plans to list on the Nasdaq under the symbol ASLN. Leerink Partners and Piper Jaffray acted as lead managers on the deal.
The article ASLAN Pharmaceuticals prices downsized US IPO at $7.03 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
